Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Tesaro, Inc.

Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to Patient

Release Date: October 31, 2018
Expiration Date: October 31, 2019
Media: Internet - based


Activity Overview

This activity, Oncology Consultations® in Ovarian Cancer: Differentiating Among Clinical Trial Designs to Match PARP to Patient, developed in the Physicians’ Education Resource, LLC, (PER®) established Oncology Consultations® legacy format, focuses on the landscape of clinical trial design and key data guiding the use of PARP inhibitors in ovarian cancer. This presentation features Dr. Susana Campos and Dr. Shannon Westin reviewing the study designs that led to current and emerging indications for the use of PARP inhibitors and discussing ongoing clinical trials in this field. Throughout this activity, they provide their expert viewpoints on the role of PARP inhibitors in ovarian cancer, including placing cutting-edge data into the context of case-based discussion to guide the use of PARP inhibitors for treatment of your patients.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Tesaro, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video Files” will be available for your reference.
  • To receive a CME/CE certificate, participants must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, gynecologic oncologists, radiation oncologists, surgical oncologists, and other health care professionals who manage and treat patients with ovarian cancer.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Differentiate among recent clinical trials of PARP inhibitors with respect to trial design and clinical outcomes
  2. Develop strategies to recognize and manage adverse events of PARP inhibitor therapies among patients with ovarian cancer
  3. Utilize knowledge of clinical trial designs, results, and patient-specific characteristics to personalize a treatment plan in the care of patients with ovarian cancer

Faculty, Staff, and Planners' Disclosures


Susana Campos, MD
Assistant Professor of Medicine
Harvard Medical School
Dana Farber Cancer Institute
Boston, MA

Disclosure: Consultant: Clovis

Shannon N. Westin, MD, MPH, FACOG
Associate Professor
Department of Gynecologic Oncology and Reproductive Medicine
Director, Early Drug Development
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/Research Support: AstraZeneca, Genentech, Clovis, Tesaro, Bayer, Novartis, Cotinga Pharmaceuticals; Consultant: AstraZeneca, Roche/Genentech, Clovis, Tesaro, Merck, Ovation, Medivation, OncLive, Medscape

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By